Charles River Laboratories

CRL

Market cap $8.37B

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces Scientific Advisory Board, led by Dr. Namandjé N. Bumpus, to support industry adoption of NAMs.

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call.

Here are three resilient medical services stocks, Labcorp, Charles River Laboratories and Teladoc, that are poised to outperform amid staffing shortages and digital healthcare growth.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River &Toxys announce collaboration to validate use of ReproTracker®, an in vitro alternative for developmental & reproductive toxicology.

Charles River Laboratories International Inc. (NYSE:CRL) is entering a critical point in its 18-phase Adhishthana cycle. The stock currently sits in Phase 17 on the weekly chart, with Phase 18, its final phase, set to begin on October 20.

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Chief Financial Officer Transition.

Charles River shares rise after new collaborations with PICI and CHLA, boosting its oncology and cell therapy pipeline momentum.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River collaborates to enhance oncology manufacturing portfolio by advancing development of cell and gene therapies to treat cancer.

Charles River Laboratories International, Inc. (NYSE:CRL ) Baird 2025 Global Healthcare Conference September 10, 2025 9:40 AM EDT Company Participants James Foster - Chairman, President & CEO Conference Call Participants Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Presentation Eric Coldwell Senior Research Analyst Good morning, everyone.

Charles River Laboratories International, Inc. (NYSE:CRL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants James Foster - Chairman, President & CEO Conference Call Participants Kallum Titchmarsh - Morgan Stanley, Research Division Presentation Kallum Titchmarsh Equity Analyst Okay. Great. I think we can get started.